Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 15503 | 638 | 43.1 | 86% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 532 | 14062 | TOLL LIKE RECEPTOR//TOLL LIKE RECEPTORS//CD14 |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | ENDOTOXIN TOLERANCE | Author keyword | 30 | 39% | 10% | 61 |
| 2 | LPS TOLERANCE | Author keyword | 8 | 48% | 2% | 12 |
| 3 | IRAK M | Author keyword | 3 | 30% | 1% | 8 |
| 4 | UP CYTOKINES INFLAMMAT | Address | 3 | 35% | 1% | 6 |
| 5 | LIPOPOLYSACCHARIDE TOLERANCE | Author keyword | 2 | 38% | 1% | 5 |
| 6 | ENDOTOXIN PRETREATMENT | Author keyword | 2 | 67% | 0% | 2 |
| 7 | IMMUNOGENET DIS | Address | 2 | 67% | 0% | 2 |
| 8 | INVEST DERMATOL IMMUNODEFICIENCY | Address | 1 | 100% | 0% | 2 |
| 9 | INTERDISCIPLINARY PHD PROGRAM GENET BIOINFORMAT | Address | 1 | 40% | 0% | 2 |
| 10 | SERV P DIS | Address | 1 | 40% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ENDOTOXIN TOLERANCE | 30 | 39% | 10% | 61 | Search ENDOTOXIN+TOLERANCE | Search ENDOTOXIN+TOLERANCE |
| 2 | LPS TOLERANCE | 8 | 48% | 2% | 12 | Search LPS+TOLERANCE | Search LPS+TOLERANCE |
| 3 | IRAK M | 3 | 30% | 1% | 8 | Search IRAK+M | Search IRAK+M |
| 4 | LIPOPOLYSACCHARIDE TOLERANCE | 2 | 38% | 1% | 5 | Search LIPOPOLYSACCHARIDE+TOLERANCE | Search LIPOPOLYSACCHARIDE+TOLERANCE |
| 5 | ENDOTOXIN PRETREATMENT | 2 | 67% | 0% | 2 | Search ENDOTOXIN+PRETREATMENT | Search ENDOTOXIN+PRETREATMENT |
| 6 | HUMAN ENDOTOXEMIA | 1 | 27% | 0% | 3 | Search HUMAN+ENDOTOXEMIA | Search HUMAN+ENDOTOXEMIA |
| 7 | 4 HYDROXY 2 NONENAL MODIFIED PROTEINS | 1 | 50% | 0% | 1 | Search 4+HYDROXY+2+NONENAL+MODIFIED+PROTEINS | Search 4+HYDROXY+2+NONENAL+MODIFIED+PROTEINS |
| 8 | CD14 RECEPTORS | 1 | 50% | 0% | 1 | Search CD14+RECEPTORS | Search CD14+RECEPTORS |
| 9 | HUMAN ENDOTOXEMIA MODEL | 1 | 50% | 0% | 1 | Search HUMAN+ENDOTOXEMIA+MODEL | Search HUMAN+ENDOTOXEMIA+MODEL |
| 10 | J7742 | 1 | 50% | 0% | 1 | Search J7742 | Search J7742 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | ENDOTOXIN TOLERANCE | 48 | 27% | 24% | 155 |
| 2 | LIPOPOLYSACCHARIDE TOLERANCE | 25 | 70% | 3% | 21 |
| 3 | IMPAIRED ANTIGEN PRESENTATION | 9 | 67% | 1% | 8 |
| 4 | INVITRO CYTOKINE PRODUCTION | 7 | 53% | 2% | 10 |
| 5 | IRAK M | 7 | 23% | 4% | 25 |
| 6 | LPS PRETREATMENT | 5 | 54% | 1% | 7 |
| 7 | EARLY ENDOTOXIN TOLERANCE | 5 | 50% | 1% | 7 |
| 8 | LPS TOLERANCE | 4 | 67% | 1% | 4 |
| 9 | INVITRO DESENSITIZATION | 4 | 75% | 0% | 3 |
| 10 | PRETREATMENT PROTECTS | 4 | 50% | 1% | 6 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Endotoxin tolerance: new mechanisms, molecules and clinical significance | 2009 | 332 | 109 | 37% |
| MicroRNA in TLR signaling and endotoxin tolerance | 2011 | 68 | 228 | 36% |
| Molecular Mechanisms and Pathological Consequences of Endotoxin Tolerance and Priming | 2012 | 28 | 48 | 40% |
| Endotoxin tolerance: A review | 2002 | 222 | 117 | 65% |
| Bench-to-bedside review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis | 2006 | 163 | 83 | 43% |
| The emerging role of microRNA in regulation of endotoxin tolerance | 2012 | 13 | 62 | 35% |
| MOLECULAR MECHANISM IN TOLERANCE TO LIPOPOLYSACCHARIDE | 1995 | 246 | 106 | 40% |
| Gene-Specific Epigenetic Regulation in Serious Infections with Systemic Inflammation | 2010 | 18 | 52 | 38% |
| Epigenetics, bioenergetics, and microRNA coordinate gene-specific reprogramming during acute systemic inflammation | 2011 | 27 | 66 | 33% |
| Endotoxin tolerance - current concepts in historical perspective | 2002 | 58 | 114 | 72% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | UP CYTOKINES INFLAMMAT | 3 | 35% | 0.9% | 6 |
| 2 | IMMUNOGENET DIS | 2 | 67% | 0.3% | 2 |
| 3 | INVEST DERMATOL IMMUNODEFICIENCY | 1 | 100% | 0.3% | 2 |
| 4 | INTERDISCIPLINARY PHD PROGRAM GENET BIOINFORMAT | 1 | 40% | 0.3% | 2 |
| 5 | SERV P DIS | 1 | 40% | 0.3% | 2 |
| 6 | CYTOKINES INFLAMMAT UNIT | 1 | 25% | 0.5% | 3 |
| 7 | BALTIMORE UMB | 1 | 50% | 0.2% | 1 |
| 8 | BIT MED CONVERGENCE PROGRAM | 1 | 50% | 0.2% | 1 |
| 9 | BURNS ALLEN PEDIAT INFECT DIS | 1 | 50% | 0.2% | 1 |
| 10 | CRIT CARE MED BIOENGN ANESTHESIOL | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000227001 | IMMUNOPARALYSIS//ANESTHESIOL MED SURG//CECAL LIGATION AND PUNCTURE |
| 2 | 0.0000175635 | TIR DOMAIN//PELLINO//INNATE IMMUN INFLAMMAT |
| 3 | 0.0000166027 | MD 2//CD14//LIPOPOLYSACCHARIDE BINDING PROTEIN |
| 4 | 0.0000111433 | BURSAL DISEASE VIRUS BDV//VIRUS VACCINE THERAPY//DECOMPENSATED HEPATITIS |
| 5 | 0.0000092607 | LPS HYPERSENSITIVITY//CORYNEBACTERIUM PARVUM//NCPP |
| 6 | 0.0000074858 | ANTILIPID A//ELEBUTE SCORE//ANTIBIOTIC INDUCED ENDOTOXIN RELEASE |
| 7 | 0.0000068736 | INFLAMMAT REGENERAT MODELING//DENSE DATA CAPTURE//AUTONOMIC INFORMATION FLOW |
| 8 | 0.0000066053 | LPS INDUCED ACUTE LUNG INJURY//ACUTE LUNG INJURY ALI//PROTOCATECHUIC ACID PCA |
| 9 | 0.0000062716 | EXPT LUNG//MACROPHAGE SECRETORY PRODUCTS//LUNG INFLAMMAT INFECT |
| 10 | 0.0000060273 | D GALACTOSAMINE//BICYCLOL//CON A INDUCED HEPATITIS |